
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult the stockbroker or other licensed securities dealer, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your Shares in Wuhan Dazhong Dental Medical Co., Ltd., you should at once hand this circular, together with the accompanying proxy form to the purchaser(s) or the transferee(s), or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser(s) or the transferee(s).

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



Wuhan Dazhong Dental Medical Co., Ltd.

武漢大眾口腔醫療股份有限公司

(A joint stock company with limited liability incorporated in the People's Republic of China)

(Stock Code: 2651)

SUPPLEMENTAL CIRCULAR TO THE CIRCULAR

DATED AUGUST 31, 2026

(1) PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR

AND

(2) SUPPLEMENTAL NOTICE OF THE EXTRAORDINARY GENERAL MEETING

This supplemental circular should be read in conjunction with the circular of the Company dated August 31, 2026 (the “**Original Circular**”).

A notice (the “**Original Notice**”) convening the extraordinary general meeting (“**EGM**”) of the Company to be held at No. 8 Conference Room, 11/F, Huayin Building, No. 786 Minzhu Road, Zhongnan Road Sub-District, Wuchang District, Wuhan, Hubei Province, PRC at 9:00 a.m. on Monday, September 21, 2026 has been issued by the Company on August 31, 2026. Due to the addition of the new resolution, a supplemental notice of the EGM (the “**Supplemental Notice**”) has been set out on pages 6 to 8 of this supplemental circular. The Supplemental Notice should be read in conjunction with the Original Notice.

A revised form of proxy for use at the EGM has been published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.chinadzyl.com) and has been issued to H Shareholders by means selected by the H Shareholders to receive corporate communications. If you wish to appoint a proxy to attend the EGM, you should complete the accompanying revised form of proxy in accordance with the instructions printed thereon and return it not less than 24 hours before the time appointed for holding the EGM or any adjournment thereof (as the case may be) (i.e. not later than 9:00 a.m. on Sunday, September 20, 2026). Completion and return of the revised form of proxy will not preclude you from attending and voting in person at the EGM or any adjournment thereof (as the case may be) should you so wish at that time.

All dates and times in this circular refer to Hong Kong dates and times.

September 4, 2026

CONTENTS

Page

LETTER FROM THE BOARD

1. Introduction	1
2. Proposed Appointment of Executive Director	2
3. EGM and Proxy Arrangement.	4
4. Recommendation	5
5. Responsibility Statement.	5

SUPPLEMENTAL NOTICE OF THE EXTRAORDINARY GENERAL MEETING	6
---	----------

LETTER FROM THE BOARD



Wuhan Dazhong Dental Medical Co., Ltd.

武漢大眾口腔醫療股份有限公司

(A joint stock company with limited liability incorporated in the People's Republic of China)

(Stock Code: 2651)

Executive Directors:

Mr. Yao Xue (*Chairman*)

Ms. Shen Hongmin

Mr. Guo Jiaping

Ms. Liu Hongchan

Independent non-executive Directors:

Mr. Shu Yijie

Ms. Huang Suzhen

Mr. Xie Dong

Registered Office and Headquarters:

Room 5, 11/F and Rooms 601, 608-612, 6/F

Huayin Building

No. 786 Minzhu Road

Zhongnan Road Sub-District

Wuchang District, Wuhan

Hubei Province

PRC

Principal Place of Business in Hong Kong:

Unit No. 705A, 7/F, New East Ocean Centre

No. 9 Science Museum Road

Tsim Sha Tsui

Hong Kong

September 4, 2026

To the Shareholders

Dear Sir/Madam,

SUPPLEMENTAL CIRCULAR TO THE CIRCULAR

DATED AUGUST 31, 2026

(1) PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR

AND

(2) SUPPLEMENTAL NOTICE OF THE EXTRAORDINARY GENERAL MEETING

1. INTRODUCTION

References are made to (i) the Original Circular and the Original Notice both dated August 31, 2026, which set out the time and venue of the EGM and contain the resolutions to be proposed at the EGM for the Shareholders' consideration and approval; and (ii) the announcement of the

LETTER FROM THE BOARD

Company dated September 4, 2026 (the “**Announcement**”) in relation to the proposed change of executive Director. This supplemental circular should be read in conjunction with the Original Circular. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Original Circular.

The main purpose of this supplemental circular is to provide you with further information regarding the proposed appointment of Mr. Wang Hong (王宏) (“**Mr. Wang**”) as the executive Director, and the additional ordinary resolution relating thereto to be proposed at the EGM.

2. PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR

Reference is made to the Announcement, in relation to, among other things, the change of executive Director.

The Board received the resignation letter from Mr. Guo Jiaping (郭家平) (“**Mr. Guo**”) as the executive Director and the vice general manager of the Company. Mr. Guo has resigned as the executive Director of the fourth session of the Board and the vice general manager of the Company to devote more time to his personal endeavours. Mr. Guo’s resignation shall take effect on the commencement date of the term of office of Mr. Wang’s appointment as the executive Director.

Mr. Guo has confirmed that he has no disagreement with the Board and there are no other matters relating to his resignation that need to be brought to the attention of the Shareholders and/or the Stock Exchange.

In view of the resignation of Mr. Guo, Hubei Zhongshan Medical Investment Management Co., Ltd., the controlling Shareholder of the Company, has submitted a written notice to the Company, proposing to add a new resolution at the EGM to elect Mr. Wang as the executive Director. The Board is pleased to announce that the Board has proposed to elect and appoint Mr. Wang as the executive Director.

After taking into account the nomination policy and Board diversity policy adopted by the Company, including but not limited to gender, age, cultural and educational background, ethnicity, professional experience, skills, knowledge and length of service, the Nomination Committee has recommended to the Board the nomination of Mr. Wang as a candidate for the executive Director and the resolution in relation to the recommended appointment was considered and approved by the Board on September 4, 2026, and is now proposed to the Shareholders at the EGM for consideration and approval by way of an ordinary resolution.

The biographical details of Mr. Wang are as follows:

Mr. Wang, aged 63, joined our Group in January 2021 as a vice general manager of our Company. He is primarily responsible for the daily operation of our medical institutions outside Wuhan, PRC. Mr. Wang also served as directors of various subsidiaries of the Company.

LETTER FROM THE BOARD

Mr. Wang has over 30 years of experience in medical and healthcare industry. Prior to joining the Group, he served as the sales effective manager and head of global dermatology division in Xi'an Janssen Pharmaceutical Co., Ltd. (西安楊森製藥有限公司) from May 1994 to December 2002, primarily responsible for its marketing and business development. He then successively served as the nationwide marketing director, deputy general manager of marketing and the vice president in Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (正大天晴藥業集團股份有限公司), a subsidiary of Sino Biopharmaceutical Limited (Stock code: 1177.HK), from December 2002 to December 2020, where he was responsible for its nationwide marketing and sales.

Mr. Wang obtained his associate diploma in animal husbandry from Henan University of Animal Husbandry and Economy (河南牧業經濟學院) in July 1984 and his master's degree in pathology from Shanghai Medical University (上海醫科大學) in July 1991. He also obtained an executive master of business administration degree from the National University of Singapore in August 2002.

Mr. Wang will enter into a service contract with the Company to serve as an executive Director for a term commencing on the date of approval by the Shareholders of his appointment at the EGM and ending on the earlier of (i) the third annual general meeting of the Company held after the date of his appointment, (ii) the expiry of the term of the current session of the Board, or (iii) the completion of three years from the date of his appointment. Mr. Wang will not receive any remuneration, including director fee, salary, bonus and allowance for his appointment as an executive Director. As the vice general manager of our Company, he is entitled to an annual salary of RMB480,000.

As at the date of this supplemental circular, Mr. Wang holds 103,000 Unlisted shares, representing 0.32% of the total number of the issued Unlisted Shares and 0.20% of the total number of the issued Shares and 10,000 H shares, representing 0.05% of the total number of the issued H Shares and 0.02% of the total number of the issued Shares. In addition, Mr. Wang holds 3,000,000 shares in Hubei Zhongshan Medical Investment Management Co., Ltd. ("**Zhongshan Medical Investment**"), representing approximately 2.58% of the equity interest in Zhongshan Medical Investment. As at the date of this supplemental circular, Zhongshan Medical Investment holds 31,324,102 Unlisted Shares, representing 96.82% of the total number of the issued Unlisted Shares and 61.93% of the total number of the issued Shares.

Save as disclosed above, as at the date of this supplemental circular, Mr. Wang (i) does not have any other interests in the Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) has not held any other positions with the Company or other members of the Group; (iii) has not been a director of any public company, the securities of which are listed on any securities market in Hong Kong or overseas, in the last three years and other major appointments and professional qualifications; (iv) does not have any relationship with any Director, senior management or substantial or controlling Shareholders; (v) has no other information that needs to be disclosed pursuant to paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules; and (vi) has no other matter that needs to be brought to the attention of the Shareholders.

LETTER FROM THE BOARD

3. EGM AND PROXY ARRANGEMENT

Due to the addition of the new resolution, the Supplemental Notice has been set out on pages 6 to 8 of this supplemental circular. At the EGM, a resolution will be proposed to approve, the proposed appointment of Mr. Wang as the executive Director.

A revised form of proxy for use at the EGM has been published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.chinadzyl.com) and has been issued to H Shareholders by means selected by the H Shareholders to receive corporate communications. If you wish to appoint a proxy to attend the EGM, you should complete the accompanying revised form of proxy in accordance with the instructions printed thereon and return it not less than 24 hours before the time appointed for holding the EGM or any adjournment thereof (as the case may be) (i.e. not later than 9:00 a.m. on Sunday, September 20, 2026). Completion and return of the revised form of proxy will not preclude you from attending and voting in person at the EGM or any adjournment thereof (as the case may be) should you so wish at that time.

If you wish to appoint a proxy to attend and vote at the EGM on your behalf and if you have not yet returned the first proxy form issued on August 31, 2026 (the **“First Proxy Form”**), you should complete, sign and return the revised form of proxy to Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong no later than 24 hours before the time appointed for holding the EGM or any of its adjournments (as the case may be) (the **“Closing Time”**). In this case, the First Proxy Form should not be submitted.

If you wish to appoint a proxy to attend and vote at the EGM on your behalf, and have already duly completed and submitted the First Proxy Form, you should note that: (a) if the revised form of proxy is not submitted, the First Proxy Form correctly completed and duly lodged will be treated as a valid proxy form submitted by you. The proxy so appointed shall be required to vote in such manner as he/she may be directed under the First Proxy Form and, in respect of the resolution set out in the Supplemental Notice, the proxy will be entitled to vote at his/her discretion or to abstain from voting on such resolution; (b) if the revised form of proxy is duly completed and submitted by the Closing Time, such revised form of proxy will supersede the First Proxy Form submitted by you. The revised form of proxy will be treated as a valid proxy form submitted by you; and (c) if the revised form of proxy is submitted after the Closing Time, such revised form of proxy will be invalid and the validity of the First Proxy Form correctly completed and duly submitted by you will not be affected. The proxy appointed by you under the First Proxy Form (if duly completed) will be entitled to vote in the manner as mentioned in (a), as if the revised form of proxy is not lodged.

In accordance with Rule 13.39(4) of the Listing Rules, any vote of Shareholders at the EGM must be taken by poll.

LETTER FROM THE BOARD

4. RECOMMENDATION

The Board considers that all resolutions set out in the notice of the EGM to be considered and approved by the Shareholders are in the interests of the Company and the Shareholders as a whole. Accordingly, the Board recommends the Shareholders to vote in favour of all the resolutions to be proposed at the EGM as set out in the Original Notice and the Supplemental Notice.

5. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable inquiries, confirm that to the best of their knowledge and belief, the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

Yours faithfully,
By order of the Board
Wuhan Dazhong Dental Medical Co., Ltd.
Mr. Yao Xue
Chairman and Executive Director

Wuhan, Hubei Province, PRC

SUPPLEMENTAL NOTICE OF THE EXTRAORDINARY GENERAL MEETING



Wuhan Dazhong Dental Medical Co., Ltd.

武漢大眾口腔醫療股份有限公司

(A joint stock company with limited liability incorporated in the People's Republic of China)

(Stock Code: 2651)

SUPPLEMENTAL NOTICE OF THE EXTRAORDINARY GENERAL MEETING

Reference is made to the notice (the “**Original Notice**”) of the extraordinary general meeting (the “**EGM**”) of the Company dated August 31, 2026 which sets out the resolutions to be considered and, if thought fit, to be approved at the EGM to be held at No. 8 Conference Room, 11/F, Huayin Building, No. 786 Minzhu Road, Zhongnan Road Sub-District, Wuchang District, Wuhan, Hubei Province, PRC at 9:00 a.m. on Monday, September 21, 2026.

SUPPLEMENTAL NOTICE IS HEREBY GIVEN that the EGM will be held as originally scheduled at the same time and venue. In addition to the resolutions contained in the Original Notice, the following resolution will also be considered and approved, if thought fit, at the EGM. This supplemental notice should be read in conjunction with the Original Notice:

ORDINARY RESOLUTION

3. To consider and approve the resolution in relation to the appointment of Mr. Wang Hong as an executive Director.

By order of the Board

Wuhan Dazhong Dental Medical Co., Ltd.

Mr. Yao Xue

Chairman and Executive Director

Wuhan, Hubei Province, PRC

September 4, 2026

SUPPLEMENTAL NOTICE OF THE EXTRAORDINARY GENERAL MEETING

Notes:

1. In order to determine the list of shareholders of the Company (the “**Shareholders**”) entitled to attend and vote at the EGM, the register of members of the Company will be closed from Wednesday, September 16, 2026 to Monday, September 21, 2026 (both days inclusive) during which period no transfer of shares of the Company will be registered. To ascertain the Shareholders’ entitlement to attend and vote at the EGM, all properly completed share transfer forms accompanied by the relevant share certificates must be lodged with the Company’s H Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong (in respect of H Shareholders) or the Company’s Board office at Room 5, 11/F and Rooms 601, 608-612, 6/F, Huayin Building, No. 786 Minzhu Road, Zhongnan Road Sub-District, Wuchang District, Wuhan, Hubei Province, PRC (in respect of Unlisted Shareholders), no later than 4:30 p.m. on Tuesday, September 15, 2026. Shareholders whose names appear on the register of members of the Company on Monday, September 21, 2026 are entitled to attend and vote at the EGM.
2. Any Shareholder entitled to attend and vote at the EGM is entitled to appoint one or more proxies to attend and vote in his/her/its stead. A proxy need not be a shareholder of the Company but must attend the EGM in person to represent the relevant Shareholder.

The instrument appointing a proxy must be in writing under the hand of the Shareholder or his/her/its attorney duly authorized in writing. If the Shareholder is a corporation, that instrument must be executed either under its common seal or under the hand of its Director(s) or duly authorized attorney. If that instrument is signed by an attorney of the Shareholder, the power of attorney authorizing that attorney to sign or other authorization documents must be notarized.

The Shareholder must deposit the revised form of proxy together with the notarized power of attorney or other authorization documents (if any) at the Company’s H Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong (in respect of H Shareholders) or the Company’s Board office at Room 5, 11/F and Rooms 601, 608-612, 6/F, Huayin Building, No. 786 Minzhu Road, Zhongnan Road Sub-District, Wuchang District, Wuhan, Hubei Province, PRC (in respect of Unlisted Shareholders), not less than 24 hours before the time appointed for holding the EGM or any adjournment thereof (as the case may be) (i.e. not later than 9:00 a.m. on Sunday, September 20, 2026). Completion and return of the revised form of proxy will not preclude Shareholders from attending and voting in person at the EGM or any adjournment thereof (as the case may be) should they so wish at that time.

If you wish to appoint a proxy to attend and vote at the EGM on your behalf and if you have not yet returned the first proxy form (the “**First Proxy Form**”) issued on August 31, 2026, you should complete, sign and return the accompanying Revised Proxy Form to Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong no later than 24 hours before the time appointed for holding the EGM or any of its adjournments (as the case may be) (the “**Closing Time**”). In this case, the First Proxy Form should not be submitted.

If you wish to appoint a proxy to attend and vote at the EGM on your behalf, and have already duly completed and submitted the First Proxy Form to the Company, you should note that:

- (a) if no revised proxy form is submitted to the Company, the First Proxy Form correctly completed and duly lodged will be treated as a valid proxy form submitted by you. The proxy so appointed shall be required to vote in such manner as he/she may be directed under the First Proxy Form and, in respect of the resolutions set out in this supplemental notice, the proxy will be entitled to vote at his/her discretion or to abstain from voting on such resolutions;
- (b) if the revised proxy form is duly completed and submitted by the Closing Time, such Revised Proxy Form will revoke and supersede the First Proxy Form submitted by you. Such Revised Proxy Form will be treated as a valid proxy form submitted by you; and
- (c) if the revised proxy form is submitted after the Closing Time, such revised proxy form will be invalid and the validity of the First Proxy Form correctly completed and duly submitted by you will not be affected. The proxy appointed by you under the First Proxy Form (if duly completed) will be entitled to vote in the manner as mentioned in (a), as if the revised proxy form is not lodged.

SUPPLEMENTAL NOTICE OF THE EXTRAORDINARY GENERAL MEETING

3. In accordance with Rule 13.39(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, any vote of Shareholders at a general meeting must be taken by poll. Accordingly, voting on the resolutions set out in the notice of the EGM will be conducted by way of poll.
4. The EGM is expected to last for half a day. Shareholders or their appointed proxies attending the EGM or any adjournment thereof (as the case may be) shall produce their identity documents. Shareholders or their appointed proxies attending the EGM shall be responsible for their own transportation and accommodation expenses.
5. In this notice of the EGM, unless the context otherwise requires, terms used herein shall have the same meanings as defined in the circular of the Company dated August 31, 2026.
6. If the attending Shareholder is a corporation, its legal representative shall present his or her ID card, a valid certificate proving his or her qualification as a legal representative and proof of shareholding; if a proxy is appointed to attend the meeting, such proxy shall present his or her ID card and a written power of attorney issued by the relevant Shareholder in accordance with law.
7. All dates and times in this notice refer to Hong Kong dates and times.